Investor Relations

Ambu expands its neurology portfolio with an EEG solution that supports continued brain monitoring during MRI/CT scans, following FDA clearance and CE marking for Ambu® Neuroline™ Cup MRI/CT.

Copenhagen, Denmark, 20 August 2026 – Ambu, the global leader in single-use endoscopy, today announces 510(k) clearance from the U.S. Food and Drug Administration (FDA) and European regulatory clearance (CE marking) for its new Ambu Neuroline Cup MRI/CT solution, expanding its neurology offering.

Ambu’s Neuroline Cup MRI/CT EEG solution is designed to support continuous brain activity monitoring for critically ill patients who need to undergo MRI or CT scans. This is particularly relevant in intensive care units (ICUs), where patients suffering from critical conditions often require continuous, long-term monitoring.

The Ambu Neuroline Cup MRI/CT solution consists of:

• Ambu Neuroline Cup MRI/CT: MR-conditional cup electrodes to be placed on the patient’s head during brain activity monitoring.
• Ambu Neuroline EEG Harness: Extension cable that connects the single-use electrodes to hospitals’ existing EEG monitoring systems.

In clinical practice today, electroencephalogram (EEG) monitoring is typically interrupted during imaging if MR-conditional electrodes are not used, as standard electrodes and cables are not compatible with the magnetic conditions of MRI or CT environments. Removal before scanning and reapplication afterward lead to longer interruptions of patient monitoring and unreliable diagnostics, posing potential risks to patient safety and inefficient use of staff resources.

By using materials designed for MRI and CT environments, Ambu’s new solution allows the electrodes to remain on the patient during imaging, supporting uninterrupted monitoring and more reliable data for clinical decision-making.

The Neuroline Cup MRI/CT solution further strengthens Ambu’s broad neurology portfolio and supports the company’s long-term growth expectations of 3-5% in Anesthesia & Patient Monitoring. The U.S. market for MR-conditional EEG electrodes is estimated at approximately DKK 300 million in 2026 and is expected to grow by approximately 19% annually through 2030, making it Ambu’s largest market for MR-conditional EEG electrodes.

The company will launch the new solution in both the U.S. and Europe in the fall of 2026.

“For 50 years, Ambu has been a trusted partner in patient monitoring, delivering reliable, high-quality electrode solutions to clinicians worldwide,” says Britt Meelby Jensen, CEO of Ambu. “With our Neuroline Cup MRI/CT-solution, we support uninterrupted brain activity monitoring, delivering consistent, high-quality diagnostics, improved efficiency, and better patient outcomes.”

Read and download the full press release here.

Lisa Bedell Clive brings 25 years of capital markets experience to Ambu, including two decades at leading investment research firm Bernstein covering the European MedTech sector.

Copenhagen, Denmark, 18 August 2026 – Ambu, the global leader in single-use endoscopy, today announces the appointment of Lisa Bedell Clive as its new Head of Investor Relations, effective immediately.

Lisa joins Ambu with 25 years of capital markets experience and an extensive track record in the global healthcare sector. For the past two decades, she has been with Bernstein, one of the world's leading investment research and brokerage firms, where she most recently served as Senior Research Analyst, covering the European Medical Devices & Services sector.

Through strong industry research, deep medical device sector expertise, and close engagement with healthcare company executives, key opinion leaders, and institutional investors, Lisa has earned a reputation as one of Europe's leading healthcare analysts.

"I’m very pleased to welcome Lisa to Ambu”, says Henrik Skak Bender, Chief Financial Officer of Ambu. “She is a highly respected voice in the MedTech investor community and brings a strong combination of capital markets expertise, industry insight, and investor relationships. Drawing on two decades of experience analyzing global MedTech companies, Lisa understands what drives long-term value creation in MedTech and the opportunities ahead of Ambu. She will play an instrumental role as we continue to strengthen our engagement with investors and execute on Ambu's next phase of growth."

Lisa grew up in the United States but has spent most of her professional life in London, giving her a unique perspective on the global healthcare landscape. In addition to her broad MedTech industry expertise, she is recognized for her insights into emerging healthcare trends, including artificial intelligence, and the shift toward value-based care.

“I’m thrilled to be joining Ambu at such an exciting time, as the company reshapes the global endoscopy market for the benefit of patients, clinicians, and health systems,” says Lisa Bedell Clive, incoming Head of IR at Ambu. “After two decades as a sell-side MedTech analyst, joining Ambu is a natural next step. Ambu stands out as one of the most compelling growth stories in MedTech, combining leadership in single-use endoscopy with a proven ability to expand and develop its end-markets. I look forward to helping investors understand how Ambu’s strategy, technological edge, and market-development capabilities translate into durable, profitable growth.”

Read the full press release here.

On 6 May 2026, Ambu announced a share buyback program (company announcement no. 12 2025/26). The share buyback program is carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) (as amended) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, also referred to as the Safe Harbor Regulations.

During the program, Ambu will repurchase shares for a total amount of up to DKK 300m from 6 May 2026 until no later than 30 September 2026. The repurchased shares are bought with the aim of completing a share capital decrease as set out in Article 5(2)(a) in MAR.

The following transactions have been made under the program from 10 Aug 2026 to 14 Aug 2026:
 

After the above disclosed transactions DKK 74,957,029 remains to be repurchased. Ambu now owns 7,567,640 treasury shares, corresponding to 2.8% of the share capital.

Download the full company announcement here.